Tregs accumulate in tumors through three ways: circulating tTregs are recruited into tumor nodules; the conventional CD4+ Foxp3− (Tconv cells) are converted of into pTregs cells under the influence of tumor‐derived factors including TGF‐β; and tissue‐resident Tregs proliferate on site (Stockis et al, 2019). Here, FOXP3 is linked to neoplasm.